|MDACC Study No:||2013-0321 (clinicaltrials.gov NCT No: NCT01873703)|
|Title:||A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS)|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||Azacitidine; Placebo; Pracinostat|
|Study Description:||The goal of this clinical research study is to learn if pracinostat given with |
azacitidine can control MDS better than azacitidine alone. The side effects of
this treatment will also be studied.